OraLiva awarded $1.9M National Institute of Dental and Craniofacial Research (NIDCR at NIH) Direct to Phase II SBIR grant for AI-linked cytomics-on-a-chip Read More
OraLiva’s ONC IN-CYT platform is a pipeline of oncology diagnostics leveraging cross indication biomarker cyto-signatures
Cancer is a disease of cellular dysregulation, making cytology ideal for profiling risk. OraLiva’s ONC In-Cyt platform combines a sophisticated microfluidics engine, automated fluorescence imaging system, and carefully tuned AI algorithms trained on millions of single-cell characteristics. By enabling rapid quantitative cytology from anywhere in the world, the ONC In-Cyt platform has the potential to transform early cancer detection.
With integrated reagents, self-contained fluidic routing and waste storage, cell isolation and staining capabilities, the OraLiva microfluidic engine delivers high-content single-cell measurements in near real-time.
The ONC In-Cyt analyzer integrates multi-spectral fluorescence imaging, automated precision fluid metering, and powerful image analysis algorithms into a user-friendly, portable bench-top device.
Delivering accuracy, speed, and accessibility for early cancer detection.
Cartridges tailored for specific use cases, from oral cancer screening to other cytology-based diagnostics.
OraLiva’s agile ONC In-Cyt platform allows for rapid expansion to a large menu of tests for different cancer sites.
OraLiva is launching its platform with a focus on oral cancer, leveraging its proprietary technology, diagnostic models, and cross-indication biomarkers to build a robust pipeline of oncology tests.
US population suffer from oral lesions complications.
Late stage treatment can cost $100K+ per patient.
Today doctors and dentists lack trusted tools to evaluate these oral lesions. In far too many cases these lesions become malignant.
Late detection of different types of solid tumor cancers remains an issue resulting in higher costs for treatment, hospital stays, in addition to often disastrous patient outcomes.
OraLiva has developed a novel cytology platform to detect the presence of oral, lung, esophageal and colorectal cancer using common biomarker signatures.
AI empowered & data-driven fingerprints for early disease detection.
Oralive sees cancer better than anyone else.
Join the OraLiva waitlist for product launch news and insights designed to support your team and improve early cancer detection in everyday care.
Join OraLiva's Waitlist
